Ionis Pharmaceuticals Inc (IONS)

30.52
-0.76(-2.43%)
After Hours
29.78
-0.74(-2.42%)
- Real-time Data
  • Volume:
    1,302,156
  • Bid/Ask:
    29.78/31.90
  • Day's Range:
    30.30 - 31.61

IONS Overview

Prev. Close
31.28
Day's Range
30.3-31.61
Revenue
687.72M
Open
31.3
52 wk Range
29.01-64.37
EPS
-3.86
Volume
1,302,156
Market Cap
4.31B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
916,766
P/E Ratio
-
Beta
1.01
1-Year Change
-35.61%
Shares Outstanding
141,147,698
Next Earnings Date
Nov 10, 2021
What is your sentiment on Ionis Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Ionis Pharmaceuticals Inc News

Ionis Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryBuyStrong SellStrong SellStrong SellStrong Sell

Ionis Pharmaceuticals Inc Company Profile

Ionis Pharmaceuticals Inc Company Profile

Employees
757

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).

Read More
  • What’s about this stock? Any new therapies are coming out?
    0
    • I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
      0
  • Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
    0
    • Added 4000 at 34.4
      0
      • nice after market move!
        0
        • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
          0
          • CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
            0
            • this stock doesn't know what a green day looks like.
              0
              • ㅜㅜ~
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.